This company listing is no longer active
ME1 Stock Overview
Engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Melodiol Global Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.001 |
| 52 Week High | AU$2.40 |
| 52 Week Low | AU$0.001 |
| Beta | 2.5 |
| 1 Month Change | 0% |
| 3 Month Change | -50.00% |
| 1 Year Change | -99.94% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny
May 01
Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding
Mar 02Shareholder Returns
| ME1 | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | 1.3% |
| 1Y | -99.9% | -8.4% | 9.5% |
Return vs Industry: ME1 underperformed the Australian Pharmaceuticals industry which returned 74.7% over the past year.
Return vs Market: ME1 underperformed the Australian Market which returned 19.4% over the past year.
Price Volatility
| ME1 volatility | |
|---|---|
| ME1 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: ME1's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine ME1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Will Lay | melodiolglobalhealth.com |
Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023.
Melodiol Global Health Limited Fundamentals Summary
| ME1 fundamental statistics | |
|---|---|
| Market cap | AU$1.13m |
| Earnings (TTM) | -AU$35.52m |
| Revenue (TTM) | AU$18.92m |
0.1x
P/S Ratio0.0x
P/E RatioIs ME1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ME1 income statement (TTM) | |
|---|---|
| Revenue | AU$18.92m |
| Cost of Revenue | AU$18.10m |
| Gross Profit | AU$817.00k |
| Other Expenses | AU$36.34m |
| Earnings | -AU$35.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 4.32% |
| Net Profit Margin | -187.73% |
| Debt/Equity Ratio | -232.0% |
How did ME1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/31 19:41 |
| End of Day Share Price | 2024/08/28 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Melodiol Global Health Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|